Publication details

Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry.

Authors

MEIJER Joost M RASHID Hanan VERGADI Styliani ANTIGA Emiliano VEZZOLI Pamela BALESTRI Riccardo PATSATSI Aikaterini UZUN Soner SKILJEVIC Dusan JEDLIČKOVÁ Hana VOJTĚCHOVÁ Lucia CORRA Alberto PONZIANI Alessandra GÜNTHER Claudia CIANCHINI Giuseppe SCHEFZYK Matthias MARZANO Angelo GIOVANNI Di Zenzo SHIMANOVICH Iakov FAIRLEY Janet MASCARÓ Jose M CAPRONI Marzia MAGLIE Roberto SCHMIDT Enno HORVÁTH Barbara

Year of publication 2023
Type Article in Periodical
Magazine / Source JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
MU Faculty or unit

Faculty of Medicine

Citation
Web https://onlinelibrary.wiley.com/doi/10.1111/jdv.19242
Doi http://dx.doi.org/10.1111/jdv.19242
Keywords COVID-19; autoimmune bullous diseases
Description For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ?10?mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.

You are running an old browser version. We recommend updating your browser to its latest version.

More info